Core Insights - Caris Life Sciences will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call to discuss these results [1] Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, focused on developing and commercializing innovative healthcare solutions [2] - The company utilizes comprehensive molecular profiling, including Whole Genome, Whole Exome, and Whole Transcriptome Sequencing, combined with advanced AI and machine learning to analyze the molecular complexity of diseases [2] - Caris has established a large-scale, multimodal clinico-genomic database and computing capability, which supports the development of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development [2] Company Background - Founded with the vision to harness the potential of precision medicine to enhance human health, Caris Life Sciences is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [3] - The company or its distributor partners provide services in the U.S. and various international markets [3]

Core Insights - Caris Life Sciences has published a study in Nature's npj Breast Cancer journal that identifies mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer, highlighting the variability in patient responses and the evolution of resistance over time [1][2] Group 1: Study Findings - The study addresses the critical gap in understanding the varied responses to T-DXd, an FDA-approved treatment for HER2-positive and HER2-low metastatic breast cancer, as resistance is common [2] - Utilizing large-scale real-world clinical outcomes and comprehensive molecular profiling, the study enables a population-level analysis of resistance pathways across DNA, RNA, and protein expression [2] - The analysis included 2,799 T-DXd-treated breast cancer patients, identifying ERBB2 (HER2) and ABCC1 as the strongest transcriptomic predictors of T-DXd-specific overall survival, with higher ERBB2 expression correlating with improved outcomes and higher ABCC1 correlating with poorer outcomes [3] Group 2: Implications for Treatment - ABCC1 further stratified outcomes within HER2-defined subgroups, indicating predictive value beyond standard HER2 testing, with post-treatment samples showing increased ABCC1 expression and mutations in ERBB2, NFE2L2, KEAP1, and TOP1, consistent with acquired resistance mechanisms [4] - The study demonstrates how population-scale, multiomic real-world data can drive high-impact translational discoveries, providing actionable insights into resistance biology to guide next-generation drug development [5] Group 3: Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company focused on precision medicine, developing innovative solutions to transform healthcare through comprehensive molecular profiling and advanced AI applications [6] - The company has created a large-scale multimodal clinico-genomic database and computing capability to analyze the molecular complexity of diseases, enhancing precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection, and drug development [6]

Company Overview - Caris Life Sciences went public in June of the previous year, marking a significant milestone as a publicly traded company [2][3] - The company is positioned for transformation in 2025, indicating a strategic focus on growth and development [3] Financial Performance - Caris Life Sciences ended the year with over $800 million in cash, reflecting a 5% increase through the quarter [3] - The company has reported strong performance from a profit and loss perspective, indicating improved financial health post-IPO [3]

Summary of Caris Life Sciences FY Conference Call Company Overview - **Company**: Caris Life Sciences (NasdaqGS:CAI) - **Date of Conference**: January 12, 2026 - **Key Speakers**: Brian Brille (Vice Chairman), David Spetzler (President), Luke Power (CFO) Key Points Financial Performance - Caris ended the year with over **$800 million** in cash, reflecting a **5% increase** through the quarter [2][3] - Revenue for Q4 was **$281 million**, representing a **116% year-over-year growth** [16][27] - The average selling price (ASP) for tissue tests increased to **$3,800** from **$3,500** in Q3, while blood tests rose to **$2,500** [34][60] Market Position and Growth Opportunities - The therapy selection business remains a core growth engine with consistent clinical case volumes and increasing pricing [4][15] - Caris completed nearly **200,000 genomic profiles** in the last year, achieving a **22% growth** in case volume [5][15] - The total addressable market (TAM) for therapy selection is large and underpenetrated, with only about **one-third** of patients receiving comprehensive genomic profiling [6][7] Product Development and Pipeline - Caris is focused on multi-cancer early detection (MCED) with promising initial results from the **AchieveOne** study, which is expected to read out by the end of the quarter [16][18] - The company is also launching **Caris ChromaSEQ**, a whole genome and whole transcriptome technology for hematological malignancies, currently under review by MolDX [19][20] - New product **MyClarity** aims to improve recurrence risk assessment for women post-surgery using AI and multimodal data [21][23] Strategic Partnerships - Caris announced a significant partnership with **Genentech**, involving a milestone payment of **$20 million** and a total contract value exceeding **$1 billion** [25] - The partnership aims to leverage Caris's data and technical capabilities to identify new drug targets [25] Commercial Strategy - The company plans to expand its commercial organization by **20%-25%** to enhance market reach and support growth [30][45] - Caris is committed to a patient-first philosophy, focusing on technology and service to cancer centers [10][11] Challenges and Future Outlook - The company acknowledges the need for insurance payers to update their medical policies regarding molecular profiling [29][30] - Caris is optimistic about the growth trajectory for 2026, driven by its technology leadership and product pipeline [15][32] Additional Insights - The market for comprehensive genomic profiling is recognized as the standard of care, with increasing demand for precision oncology programs [7][8] - Caris emphasizes the importance of maximizing biological information for patients, regardless of initial costs [17][19] - The company is focused on maintaining capital efficiency while investing in technology and commercial growth [30][45] This summary encapsulates the key insights and strategic directions discussed during the Caris Life Sciences FY Conference Call, highlighting the company's financial performance, market opportunities, product pipeline, and future outlook.

Company Overview - Caris Life Sciences has a comprehensive oncology database with over 1,016,000 molecular profiles[5] - The company has a global presence with over 1,800 employees[7] - Caris has established a Precision Oncology Alliance (POA) with 99 leading cancer centers[5] Data and Technology - The company has profiled over 1 million cases in its genomic dataset[9] - Caris possesses over 627,000 whole exomes and 678,000 whole transcriptomes[9, 11] - The company has access to over 740,000 profiles with matched molecular data and clinical outcomes[11] Market Trends and Reach - Cancer centers are standardizing molecular profiling towards technology and service leaders[13] - Caris has a field-based team of approximately 250 and 50 MSLs serving over 6,000 oncologists in the US[18] - The company has integrated ordering locations in over 3,350 EHRs[18] Financial Performance - Caris achieved $281 million in revenue in Q4 2025, representing a 116% year-over-year growth[35, 67] - The company's total revenue increased to $800 million in FY 2025, a 94% increase year-over-year[69] - Molecular profiling services revenue increased to $755 million, a 116% increase year-over-year[69]

Financial Results - Caris Life Sciences, Inc. announced preliminary unaudited financial results for Q4 and full year 2025 on January 12, 2026[5] - The report does not include specific financial figures or performance metrics for the quarter or year ended December 31, 2025[5] Upcoming Events - The company will present materials at the 2026 J.P. Morgan Healthcare Conference, which will be available on its investor relations website[6]

Core Insights - Caris Life Sciences reported a full year revenue growth of approximately 94%, driven by strong performance in molecular profiling services [1][6] - The company completed approximately 199,300 clinical therapy selection cases in 2025, marking a 22% increase from the previous year [6] - Caris aims to establish a new standard in precision medicine through its comprehensive molecular profiling platform and advanced AI technologies [3][7] Financial Performance - For the full year 2025, total revenue reached approximately $800 million, with molecular profiling services contributing about $755 million [6] - The fourth quarter of 2025 saw total revenue of approximately $281 million, an increase of about 116% compared to the same period in 2024 [6] - As of December 31, 2025, the company reported cash, cash equivalents, restricted cash, and marketable securities of approximately $802 million, reflecting a net increase of about $43 million from September 30, 2025 [2] Business Development - The company is focused on expanding clinical adoption and advancing a differentiated pipeline in precision medicine [3] - Caris Life Sciences plans to report complete financial results for the fourth quarter and full year 2025 during its earnings call in late February 2026 [5] - The company has established a large-scale, multimodal clinico-genomic database to enhance its precision medicine diagnostic solutions [7]

Core Insights - Caris Life Sciences has announced a partnership with Everlywell to launch Caris Detect, a Multi-Cancer Early Detection (MCED) blood-based screening assay utilizing whole genome sequencing (WGS) technology [1][2][3] Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, developing innovative solutions to transform healthcare through comprehensive molecular profiling and advanced AI technologies [4][5] - Everlywell is a digital health company that combines AI technology with human insight to provide personalized health answers, having delivered nearly 1 billion health insights and transformed care for 60 million people [6] Partnership Details - The partnership aims to enhance access to Caris Detect testing, which is designed to identify multiple cancer types at early stages, ultimately supporting better patient outcomes [3] - Caris expects to launch the Caris Detect assay in the first half of 2026, leveraging Everlywell's consumer-focused platform and established infrastructure [3]

Core Insights - Caris Life Sciences will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, California [1] - The company will participate in a Q&A session on January 12 at 1:30 PM PT, with live and replay webcasts available on its Investor Relations website [2] Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, focused on developing innovative solutions to transform healthcare [3] - The company utilizes comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing, alongside advanced AI and machine learning algorithms to create a large-scale clinico-genomic database [3] - Caris aims to improve the human condition through precision medicine, with headquarters in Irving, Texas, and additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [4]

Core Insights - Caris Life Sciences has announced the addition of Providence Swedish Cancer Institute and the Paul G. Allen Research Center to its Caris Precision Oncology Alliance, enhancing its network of cancer centers and research institutions dedicated to advancing precision oncology [1][3] Group 1: Company Overview - Caris Life Sciences is a leading AI TechBio company focused on precision medicine, utilizing advanced technologies to transform healthcare through comprehensive molecular profiling and AI-driven solutions [5][6] - The company aims to improve patient outcomes by leveraging a large multimodal database that includes genomic, transcriptomic, and proteomic data [4][5] Group 2: Partnership Details - The Providence Swedish Cancer Institute specializes in innovative cancer diagnosis and treatment, utilizing a multidisciplinary approach to enhance patient care from diagnosis to survivorship [2][8] - The Caris Precision Oncology Alliance now includes 99 members, comprising cancer centers, academic institutions, and healthcare systems, all collaborating to refine molecular testing standards and improve clinical outcomes [3][4] Group 3: Research and Innovation - The partnership aims to accelerate access to cutting-edge therapies by utilizing shared resources and collaborative research efforts [4][3] - Caris POA members can participate in biomarker-directed trials sponsored by biopharmaceutical companies, enhancing the potential for innovative cancer treatments [4]